The landscape of pathophysiology guided therapeutic strategies for gout treatment

References

• Grassi W, De Angelis R. Clinical features of gout. Reumatismo. 2012;63(4):238–245. doi:10.4081/reumatismo.2011.238
   PubMedGoogle Scholar
• Taylor WJ, Fransen J, Jansen TL, et al. Study for updated gout classification criteria: identification of features to classify gout. Arthritis Care Res (Hoboken). 2015;67(9):1304–1315. doi: 10.1002/acr.22585
   PubMed Web of Science ®Google Scholar
• Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380–390. doi:10.1038/s41584-020-0441-1
   PubMed Web of Science ®Google Scholar
• Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin North Am. 2014;40(2):155–175. doi:10.1016/j.rdc.2014.01.001
   PubMed Web of Science ®Google Scholar
• Cabău G, Crișan T, Klück V, et al. Urate-induced immune programming: consequences for gouty arthritis and hyperuricemia. Immunol Rev. 2020;294(1):92–105.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Gosling A, Gaffo A, et al. Gout. Lancet. 2021;397(10287):1843–1855. doi: 10.1016/S0140-6736(21)00569-9
   PubMed Web of Science ®Google Scholar
• Shi Y, Mucsi AD, Ng G. Monosodium urate crystals in inflammation and immunity. Immunol Rev. 2010;233(1):203–217. doi:10.1111/j.0105-2896.2009.00851.x
   PubMedGoogle Scholar
• Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J Inflamm Res. 2011;4:39–49. doi:10.2147/JIR.S11330
   PubMedGoogle Scholar
• Hari A, Zhang Y, Tu Z, et al. Activation of NLRP3 inflammasome by crystalline structures via cell surface contact. Sci Rep. 2014;4(1):7281.
   PubMedGoogle Scholar
• Mata R, Yao Y, Cao W, et al. The dynamic inflammatory tissue microenvironment: signality and disease therapy by biomaterials. Research (Wash D C). 2021;2021:4189516. doi:10.34133/2021/4189516
   PubMedGoogle Scholar
• Amaral FA, Costa VV, Tavares LD, et al. NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout. Arthritis Rheum. 2012;64(2):474–84. doi: 10.1002/art.33355
   PubMed Web of Science ®Google Scholar
• Kydd AS, Seth R, Buchbinder R, et al. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews. J Rheumatol. 2014;92(Suppl. 92):33–41.
   Google Scholar
• Stamp LK, Chapman PT. Urate-lowering therapy: current options and future prospects for elderly patients with gout. Drugs Aging. 2014;31(11):777–786. doi:10.1007/s40266-014-0214-0
   PubMed Web of Science ®Google Scholar
• Day RO, Kamel B, Kannangara DR, et al. Xanthine oxidoreductase and its inhibitors: relevance for gout. Clin Sci (Lond). 2016;130(23):2167–2180. doi:10.1042/CS20160010
   PubMed Web of Science ®Google Scholar
• Kydd AS, Seth R, Buchbinder R, et al. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014;11:CD010457. doi: 10.1002/14651858.CD010457.pub2
   PubMed Web of Science ®Google Scholar
• Garay RP, El-Gewely MR, Labaune JP, et al. Therapeutic perspectives on uricases for gout. Joint Bone Spine. 2012;79(3):237–242. doi:10.1016/j.jbspin.2012.01.004
   PubMed Web of Science ®Google Scholar
• van Durme CM, Wechalekar MD, Buchbinder R, et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014;9:CD010120. doi: 10.1002/14651858.CD010120.pub2
   PubMed Web of Science ®Google Scholar
• Liu X, Sun D, Ma X, et al. Benefit-risk of corticosteroids in acute gout patients: An updated meta-analysis and economic evaluation. Steroids. 2017;128:89–94. doi:10.1016/j.steroids.2017.09.002
   PubMed Web of Science ®Google Scholar
• McKenzie BJ, Wechalekar MD, Johnston RV, et al. Colchicine for acute gout. Cochrane Database Syst Rev. 2021;8(8):CD006190. doi: 10.1002/14651858.CD006190.pub3
   PubMed Web of Science ®Google Scholar
• Jordan A, Gresser U. Side effects and interactions of the Xanthine oxidase inhibitor febuxostat. Pharmaceuticals (Basel). 2018;11(2):51. doi:10.3390/ph11020051
   PubMedGoogle Scholar
• Vonkeman HE, van de Laar MA. Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum. 2010;39(4):294–312. doi:10.1016/j.semarthrit.2008.08.001
   PubMed Web of Science ®Google Scholar
• Fathallah-Shaykh SA, Cramer MT. Uric acid and the kidney. Pediatr Nephrol. 2014;29(6):999–1008. doi:10.1007/s00467-013-2549-x
   PubMed Web of Science ®Google Scholar
• Álvarez-Lario B, Macarrón-Vicente J. Uric acid and evolution. Rheumatology (Oxford). 2010;49(11):2010–2015. doi:10.1093/rheumatology/keq204
   PubMed Web of Science ®Google Scholar
• Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25(2):210–216. doi:10.1097/BOR.0b013e32835d951e
   PubMed Web of Science ®Google Scholar
• Yanai H, Adachi H, Hakoshima M, et al. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci. 2021;22(17):9221. doi: 10.3390/ijms22179221
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang Y, Cheng J, et al. Hyperuricemia and cardiovascular disease. Curr Pharm Des. 2019;25(6):700–709. doi: 10.2174/1381612825666190408122557
   PubMed Web of Science ®Google Scholar
• Lioté F. Hyperuricemia and gout. Curr Rheumatol Rep. 2003;5(3):227–34. doi:10.1007/s11926-003-0072-y
   PubMedGoogle Scholar
• Sansone A, Reisman Y, Jannini EA. Relationship between hyperuricemia with deposition and sexual dysfunction in males and females. J Endocrinol Invest. 2022;45(4):691–703. doi:10.1007/s40618-021-01719-w
   PubMed Web of Science ®Google Scholar
• Zhang WZ. Why does hyperuricemia not necessarily induce gout? Biomolecules. 2021;11(2):280. doi:10.3390/biom11020280
   PubMed Web of Science ®Google Scholar
• Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. Curr Rheumatol Rep. 2014;16(2):400. doi:10.1007/s11926-013-0400-9
   PubMed Web of Science ®Google Scholar
• Kanevets U, Sharma K, Dresser K, et al. A role of IgM antibodies in monosodium urate crystal formation and associated adjuvanticity. J Immunol. 2009;182(4):1912–1918. doi: 10.4049/jimmunol.0803777
   PubMed Web of Science ®Google Scholar
• Cabău G, Crișan TO, Klück V, et al. Urate‐induced immune programming: consequences for gouty arthritis and hyperuricemia. Immunol Rev. 2020;294(1):92–105. doi: 10.1111/imr.12833
   PubMed Web of Science ®Google Scholar
• So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017;13(11):639–647. doi:10.1038/nrrheum.2017.155
   PubMed Web of Science ®Google Scholar
• Du X, Zhang M, Zhou H, et al. Decoy nanozymes enable multitarget blockade of proinflammatory cascades for the treatment of multi-drug-resistant bacterial sepsis. Research (Wash D C). 2022;2022:9767643. doi: 10.34133/2022/9767643
   PubMedGoogle Scholar
• Oishi Y, Manabe I. Macrophages in inflammation, repair and regeneration. Int Immunol. 2018;30(11):511–528. doi:10.1093/intimm/dxy054
   PubMed Web of Science ®Google Scholar
• Martin WJ, Shaw O, Liu X, et al. Monosodium urate monohydrate crystal–recruited noninflammatory monocytes differentiate into M1-like proinflammatory macrophages in a peritoneal murine model of gout. Arthritis Rheum. 2011;63(5):1322–32. doi: 10.1002/art.30249
   PubMed Web of Science ®Google Scholar
• Nakayama M. Macrophage recognition of crystals and nanoparticles. Front Immunol. 2018;9:103. doi:10.3389/fimmu.2018.00103
   PubMed Web of Science ®Google Scholar
• Liu-Bryan R, Scott P, Sydlaske A, et al. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 2005;52(9):2936–46. doi: 10.1002/art.21238
   PubMedGoogle Scholar
• Piancone F, Saresella M, Marventano I, et al. Monosodium urate crystals activate the inflammasome in primary progressive multiple sclerosis. Front Immunol. 2018;9:983. doi: 10.3389/fimmu.2018.00983
   PubMed Web of Science ®Google Scholar
• Kelley N, Jeltema D, Duan Y, et al. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20(13):3328. doi: 10.3390/ijms20133328
   PubMed Web of Science ®Google Scholar
• Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477–489. doi:10.1038/s41577-019-0165-0
   PubMed Web of Science ®Google Scholar
• Li X, Zhang P, Yin Z, et al. Caspase-1 and gasdermin D afford the optimal targets with distinct switching strategies in NLRP1b inflammasome-induced cell death. Research (Wash D C). 2022;9838341. doi: 10.34133/2022/9838341
   PubMedGoogle Scholar
• Zheng Y, Sun W, Wang Z, et al. Activation of Pancreatic Acinar FXR protects against pancreatitis via Osgin1-mediated restoration of efficient autophagy. Research (Wash D C). 2022;2022:9784081. doi: 10.34133/2022/9784081
   PubMedGoogle Scholar
• Sansonetti PJ, Phalipon A, Arondel J, et al. Caspase-1 activation of IL-1beta and IL-18 are essential for Shigella flexneri-induced inflammation. Immunity. 2000;12(5):581–90. doi: 10.1016/S1074-7613(00)80209-5
   PubMed Web of Science ®Google Scholar
• Fei Y, Zhang S, Han S, et al. The role of dihydroresveratrol in enhancing the synergistic effect of Ligilactobacillus salivarius Li01 and resveratrol in ameliorating colitis in mice. Research (Wash D C). 2022;2022:9863845. doi: 10.34133/2022/9863845
   PubMedGoogle Scholar
• McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328–2337. doi:10.1016/S0140-6736(17)31472-1
   PubMed Web of Science ®Google Scholar
• Dinarello CA. How interleukin-1β induces gouty arthritis. Arthritis Rheum. 2010;62(11):3140–3144. doi:10.1002/art.27663
   PubMed Web of Science ®Google Scholar
• Alberts BM, Bruce C, Basnayake K, et al. Secretion of IL-1β from monocytes in gout is redox Independent. Front Immunol. 2019;10:70. doi: 10.3389/fimmu.2019.00070
   PubMed Web of Science ®Google Scholar
• Mitroulis I, Kambas K, Ritis K. Neutrophils, IL-1β, and gout: is there a link? Semin. Semin Immunopathol. 2013;35(4):501–12. doi:10.1007/s00281-013-0361-0
   PubMed Web of Science ®Google Scholar
• Steiger S, Harper JL. Mechanisms of spontaneous resolution of acute gouty inflammation. Curr Rheumatol Rep. 2014;16(1):392. doi:10.1007/s11926-013-0392-5
   PubMed Web of Science ®Google Scholar
• Chen YH, Hsieh SC, Chen WY, et al. Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFβ1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3. Ann Rheum Dis. 2011;70(9):1655–63. doi: 10.1136/ard.2010.145821
   PubMed Web of Science ®Google Scholar
• Wu M, Tian Y, Wang Q, et al. Gout: a disease involved with complicated immunoinflammatory responses: a narrative review. Clin Rheumatol. 2020;39(10):2849–2859. doi: 10.1007/s10067-020-05090-8
   PubMed Web of Science ®Google Scholar
• Zhao K, Wang X, Zhao D, et al. lncRNA HITT inhibits lactate production by repressing PKM2 oligomerization to reduce tumor growth and macrophage polarization. Research (Wash D C). 2022;2022:9854904. doi: 10.34133/2022/9854904
   PubMedGoogle Scholar
• Chen Y, Hu M, Wang L, et al. Macrophage M1/M2 polarization. Eur J Pharmacol. 2020;877:173090. doi: 10.1016/j.ejphar.2020.173090
   PubMed Web of Science ®Google Scholar
• Wang N, Liang H, Zen K. Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance. Front Immunol. 2014;5:614. doi:10.3389/fimmu.2014.00614
   PubMed Web of Science ®Google Scholar
• Schauer C, Janko C, Munoz LE, et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med. 2014;20(5):511–517. doi: 10.1038/nm.3547
   PubMed Web of Science ®Google Scholar
• Schlesinger N. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. Semin Arthritis Rheum. 2012;42(2):155–165. doi:10.1016/j.semarthrit.2012.03.010
   PubMed Web of Science ®Google Scholar
• Chhana A, Dalbeth N. The gouty tophus: a review. Curr Rheumatol Rep. 2015;17(3):19. doi:10.1007/s11926-014-0492-x
   PubMed Web of Science ®Google Scholar
• Chhana A, Callon KE, Pool B, et al. Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout. Ann Rheum Dis. 2011;70(9):1684–1691.
   PubMed Web of Science ®Google Scholar
• Chhana A, Pool B, Callon KE, et al. Monosodium urate crystals reduce osteocyte viability and indirectly promote a shift in osteocyte function towards a proinflammatory and proresorptive state. Arthritis Res Ther. 2018;20(1):208. doi: 10.1186/s13075-018-1704-y
   PubMedGoogle Scholar
• Hwang HS, Yang CM, Park SJ, et al. Monosodium urate crystal-induced chondrocyte death via autophagic process. Int J Mol Sci. 2015;16(12):29265–29277. doi: 10.3390/ijms161226164
   PubMed Web of Science ®Google Scholar
• Chhana A, Callon KE, Pool B, et al. The effects of monosodium urate monohydrate crystals on chondrocyte viability and function: implications for development of cartilage damage in gout. J Rheumatol. 2013;40(12):2067–2074. doi: 10.3899/jrheum.130708
   PubMed Web of Science ®Google Scholar
• Day RO, Kamel B, Kannangara DR, et al. Xanthine oxidoreductase and its inhibitors: relevance for gout. Clin Sci (Lond). 2016;130(23):2167–2180. doi: 10.1042/CS20160010
   PubMed Web of Science ®Google Scholar
• Vickneson K, George J. Xanthine Oxidoreductase Inhibitors. Handb Exp Pharmacol. 2021;264:205–228.
   PubMedGoogle Scholar
• Proudman C, Lester SE, Gonzalez-Chica DA, et al. Gout, flares, and allopurinol use: a population-based study. Arthritis Res Ther. 2019;21(1):132. doi: 10.1186/s13075-019-1918-7
   PubMedGoogle Scholar
• Orriss IR, Arnett TR, George J, et al. Allopurinol and oxypurinol promote osteoblast differentiation and increase bone formation. Exp Cell Res. 2016;342(2):166–174. doi: 10.1016/j.yexcr.2016.03.004
   PubMed Web of Science ®Google Scholar
• Day RO, Kannangara DR, Stocker SL, et al. Allopurinol: insights from studies of dose-response relationships. Expert Opin Drug Metab Toxicol. 2017;13(4):449–462. doi: 10.1080/17425255.2017.1269745
   PubMed Web of Science ®Google Scholar
• Stamp LK, Chapman PT, Palmer SC. Allopurinol and kidney function: an update. Joint Bone Spine. 2016;83(1):19–24. doi:10.1016/j.jbspin.2015.03.013
   PubMed Web of Science ®Google Scholar
• Bardin T, Richette P. The role of febuxostat in gout. Curr Opin Rheumatol. 2019;31(2):152–158. doi:10.1097/BOR.0000000000000573
   PubMed Web of Science ®Google Scholar
• Abeles AM, Pillinger MH. Febuxostat and the Black Box Blues. ACR Open Rheumatol. 2019;1(6):343–344. doi:10.1002/acr2.11047
   PubMedGoogle Scholar
• Luo Z, Yu G, Han X, et al. Prediction of the pharmacokinetics and pharmacodynamics of topiroxostat in humans by integrating the physiologically based pharmacokinetic model with the drug-target residence time model. Biomed Pharmacother. 2020;121:109660. doi: 10.1016/j.biopha.2019.109660
   PubMed Web of Science ®Google Scholar
• Li X, Yan Z, Tian J, et al. Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models. Ann Clin Lab Sci. 2019;49(6):756–762.
   PubMed Web of Science ®Google Scholar
• Graessler J, Graessler A, Unger S, et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum. 2006;54(1):292–300. doi: 10.1002/art.21499
   PubMedGoogle Scholar
• Azevedo VF, Kos IA, Vargas-Santos AB, et al. Benzbromarone in the treatment of gout. Adv Rheumatol. 2019;59(1):37. doi: 10.1186/s42358-019-0080-x
   PubMedGoogle Scholar
• Lee MH, Graham GG, Williams KM, et al. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31(8):643–65. doi: 10.2165/00002018-200831080-00002
   PubMed Web of Science ®Google Scholar
• Miner JN, Tan PK, Hyndman D, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18(1):214. doi: 10.1186/s13075-016-1107-x
   PubMed Web of Science ®Google Scholar
• Hoy SM. Lesinurad: First Global Approval. Drugs. 2016;76(4):509–16. doi:10.1007/s40265-016-0550-y
   PubMed Web of Science ®Google Scholar
• Piani F, Agnoletti D, Borghi C. Advances in pharmacotherapies for hyperuricemia. Expert Opin Pharmacother. 2023;24(6):737–745. doi:10.1080/14656566.2023.2197591
   PubMed Web of Science ®Google Scholar
• Shen Z, Gillen M, Miner JN, et al. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects. Drug Des Devel Ther. 2017;11:2077–2086. doi: 10.2147/DDDT.S140658
   PubMed Web of Science ®Google Scholar
• Stack AG, Dronamraju N, Parkinson J, et al. Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: a randomized trial. Am J Kidney Dis. 2021;77(4):481–489. doi: 10.1053/j.ajkd.2020.09.009
   PubMed Web of Science ®Google Scholar
• Edwards NL, So A. Emerging therapies for gout. Rheumatol Dis Clin N Am. 2014;40(2):375–387. doi:10.1016/j.rdc.2014.01.013
   PubMed Web of Science ®Google Scholar
• Poiley J, Steinberg AS, Choi YJ, et al. A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis & Rheumat. 2016;68(8):2027–2034. doi: 10.1002/art.39684
   PubMed Web of Science ®Google Scholar
• Wu XW, Lee CC, Muzny DM, et al. Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci U S A. 1989;86(23):9412–9416. doi: 10.1073/pnas.86.23.9412
   PubMed Web of Science ®Google Scholar
• Dabbagh F, Ghoshoon MB, Hemmati S, et al. Engineering Human urate oxidase: towards reactivating it as an important therapeutic enzyme. Curr Pharm Biotechnol. 2015;17(2):141–146. doi: 10.2174/1389201016666150907113055
   PubMed Web of Science ®Google Scholar
• Yeldandi AV, Wang XD, Alvares K, et al. Human urate oxidase gene: cloning and partial sequence analysis reveal a stop codon within the fifth exon. Biochem Biophys Res Commun. 1990;171(2):641–646. doi: 10.1016/0006-291X(90)91194-W
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Choi HK, Yeo AE, et al. Pegloticase treatment significantly decreases Blood pressure in patients with chronic gout. Hypertension. 2019;74(1):95–101. doi: 10.1161/HYPERTENSIONAHA.119.12727
   PubMed Web of Science ®Google Scholar
• Keenan RT, Botson JK, Masri KR, et al. The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review. Semin Arthritis Rheum. 2021;51(2):347–352. doi: 10.1016/j.semarthrit.2021.01.005
   PubMed Web of Science ®Google Scholar
• Ravandi F, Gandhi V. Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs. 2006;15(12):1601–1613. doi:10.1517/13543784.15.12.1601
   PubMed Web of Science ®Google Scholar
• Fitz-Patrick D, Drummond W, Pappas J, et al. Effects of a purine nucleoside phosphorylase inhibitor, Bcx4208, on the serum uric acid concentrations in patients with gout[abstract]. Arthritis & Rheumatism. 2010;62(Suppl 10):150.
   PubMedGoogle Scholar
• Hollister A, Dobo S, Maetzel A, et al. FRI0380 Long-term safety of BCX4208 added to allopurinol in the chronic management of GOUT: results of a phase 2 24-week blinded safety extension and vaccine challenge study. Ann Rheum Dis. 2013;71(Suppl 3):442.3–443.
   Google Scholar
• Li Z, Guo J, Bi L. Role of the NLRP3 inflammasome in autoimmune diseases. Biomed Pharmacother. 2020;130:110542. doi:10.1016/j.biopha.2020.110542
   PubMed Web of Science ®Google Scholar
• Wang L, Feng J, Deng Y, et al. Ccaat/enhancer-binding proteins in fibrosis: complex roles beyond conventional understanding. Research (Wash D C). 2022;2022:9891689. doi: 10.34133/2022/9891689
   PubMedGoogle Scholar
• Isazadeh M, Amandadi M, Haghdoust F, et al. Split-luciferase complementary assay of NLRP3 PYD-PYD interaction indicates inflammasome formation during inflammation. Anal Biochem. 2022;638:114510. doi: 10.1016/j.ab.2021.114510
   PubMed Web of Science ®Google Scholar
• Yang G, Lee HE, Moon SJ, et al. Direct binding to NLRP3 pyrin domain as a novel strategy to prevent NLRP3-driven inflammation and gouty arthritis. Arthritis & Rheumat. 2020;72(7):1192–1202. doi: 10.1002/art.41245
   PubMed Web of Science ®Google Scholar
• Zhang X, Hu L, Xu S, et al. Erianin: a direct NLRP3 inhibitor with remarkable anti-inflammatory activity. Front Immunol. 2021;12:739953. doi: 10.3389/fimmu.2021.739953
   PubMed Web of Science ®Google Scholar
• Marinho Y, Marques-da-Silva C, Santana PT, et al. MSU crystals induce sterile IL-1β secretion via P2X7 receptor activation and HMGB1 release. Biochim Biophys Acta Gen Subj. 2020;1864(1):129461. doi: 10.1016/j.bbagen.2019.129461
   PubMed Web of Science ®Google Scholar
• Gombault A, Baron L, Couillin I. ATP release and purinergic signaling in NLRP3 inflammasome activation. Front Immunol. 2013;3:414. doi:10.3389/fimmu.2012.00414
   PubMed Web of Science ®Google Scholar
• Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease. Nat Med. 2015;21(3):263–9. doi: 10.1038/nm.3804
   PubMed Web of Science ®Google Scholar
• Goldberg EL, Asher JL, Molony RD, et al. β-hydroxybutyrate deactivates neutrophil NLRP3 inflammasome to relieve gout flares. Cell Rep. 2017;18(9):2077–2087. doi: 10.1016/j.celrep.2017.02.004
   PubMed Web of Science ®Google Scholar
• Kim SK, Choe JY, Park KY. Anti-inflammatory effect of artemisinin on uric acid-induced NLRP3 inflammasome activation through blocking interaction between NLRP3 and NEK7. Biochem Biophys Res Commun. 2019;517(2):338–345. doi:10.1016/j.bbrc.2019.07.087
   PubMed Web of Science ®Google Scholar
• Misawa T, Takahama M, Kozaki T, et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013;14(5):454–460. doi: 10.1038/ni.2550
   PubMed Web of Science ®Google Scholar
• Leung YY, Yao Hui LL, Kraus VB. Colchicine–update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341–50. doi:10.1016/j.semarthrit.2015.06.013
   PubMed Web of Science ®Google Scholar
• Hastie SB. Interactions of colchicine with tubulin. Pharmacol Ther. 1991;51(3):377–401. doi:10.1016/0163-7258(91)90067-V
   PubMed Web of Science ®Google Scholar
• Misawa T, Saitoh T, Kozaki T, et al. Resveratrol inhibits the acetylated α-tubulin-mediated assembly of the NLRP3-inflammasome. Int Immunol. 2015;27(9):425–434. doi: 10.1093/intimm/dxv018
   PubMed Web of Science ®Google Scholar
• Jiang H, Chen F, Song D, et al. Dynamin-related protein 1 is involved in mitochondrial damage, defective mitophagy, and NLRP3 inflammasome activation induced by MSU crystals. Oxid Med Cell Longev. 2022;2022:5064494. doi: 10.1155/2022/5064494
   PubMed Web of Science ®Google Scholar
• Cheng G, Liu X, Liu Y, et al. Ultrasmall coordination polymers for alleviating ROS-Mediated inflammatory and realizing neuroprotection against Parkinson’s disease. Research (Wash D C). 2022;2022:9781323. doi: 10.34133/2022/9781323
   PubMedGoogle Scholar
• Yin C, Liu B, Wang P, et al. Eucalyptol alleviates inflammation and pain responses in a mouse model of gout arthritis. Br J Pharmacol. 2020;177(9):2042–2057. doi: 10.1111/bph.14967
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang C, Wang H, et al. Loganin alleviates sepsis-induced acute lung injury by regulating macrophage polarization and inhibiting NLRP3 inflammasome activation. Int Immunopharmacol. 2021;95:107529. doi: 10.1016/j.intimp.2021.107529
   PubMed Web of Science ®Google Scholar
• Chen B, Li H, Ou G, et al. Curcumin attenuates MSU crystal-induced inflammation by inhibiting the degradation of IκBα and blocking mitochondrial damage. Arthritis Res Ther. 2019;21(1):193. doi: 10.1186/s13075-019-1974-z
   PubMed Web of Science ®Google Scholar
• Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu Rev Med. 2014;65(1):223–244. doi: 10.1146/annurev-med-061512-150641
   PubMedGoogle Scholar
• Dinarello CA. Treatment of inflammatory diseases with IL-1 blockade. Curr Otorhinolaryngol Rep. 2018;6(1):1–14. doi:10.1007/s40136-018-0181-9
   PubMedGoogle Scholar
• Volarevic V, Al-Qahtani A, Arsenijevic N, et al. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity. 2010;43(4):255–263. doi: 10.3109/08916930903305641
   PubMed Web of Science ®Google Scholar
• Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol. 2018;9:1157. doi:10.3389/fphar.2018.01157
   PubMed Web of Science ®Google Scholar
• Saag KG, Khanna PP, Keenan RT, et al. A randomized, phase II study evaluating the efficacy and safety of Anakinra in the treatment of gout flares. Arthritis & Rheumat. 2021;73(8):1533–1542. doi: 10.1002/art.41699
   PubMed Web of Science ®Google Scholar
• Kapur S, Bonk ME. Rilonacept (arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes. P T. 2009;34(3):138–141.
   PubMedGoogle Scholar
• Mitha E, Schumacher HR, Fouche L, et al. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford). 2013;52(7):1285–1292. doi: 10.1093/rheumatology/ket114
   PubMed Web of Science ®Google Scholar
• Sundy JS, Schumacher HR, Kivitz A, et al. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol. 2014;41(8):1703–1711. doi: 10.3899/jrheum.131226
   PubMed Web of Science ®Google Scholar
• D’Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019;43(6):582–592. doi:10.1002/cbin.11137
   PubMed Web of Science ®Google Scholar
• Yang J, Hu S, Bian Y, et al. Targeting cell death: pyroptosis, ferroptosis, apoptosis and necroptosis in osteoarthritis. Front Cell Dev Biol. 2022;9:789948. doi: 10.3389/fcell.2021.789948
   PubMed Web of Science ®Google Scholar
• Wang H, Song Z, Xie E, et al. Targeting the LSD1-G9a-ER stress pathway as a novel therapeutic strategy for esophageal squamous cell carcinoma. Research (Wash D C). 2022;2022:9814652. doi: 10.34133/2022/9814652
   PubMedGoogle Scholar
• Frangou E, Vassilopoulos D, Boletis J, et al. An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): implications for the pathogenesis and treatment. Autoimmun Rev. 2019;18(8):751–760. doi: 10.1016/j.autrev.2019.06.011
   PubMed Web of Science ®Google Scholar
• Mutua V, Gershwin LJ. A review of neutrophil extracellular traps (NETs) in disease: potential anti-NETs therapeutics. Clin Rev Allergy Immunol. 2021;61(2):194–211. doi:10.1007/s12016-020-08804-7
   PubMed Web of Science ®Google Scholar
• Uratsuji H, Tada Y, Hau CS, et al. Monosodium Urate Crystals Induce Functional Expression of P2Y14 Receptor in Human Keratinocytes. J Invest Dermatol. 2016;136(6):1293–1296. doi: 10.1016/j.jid.2016.01.026
   PubMed Web of Science ®Google Scholar
• Liu C, Zhou M, Jiang W, et al. GPR105-targeted therapy promotes gout resolution as a switch between NETosis and apoptosis of neutrophils. Front Immunol. 2022;13:870183. doi: 10.3389/fimmu.2022.870183
   PubMed Web of Science ®Google Scholar
• Aydin E, Faehling S, Saleh M, et al. Phosphoinositide 3-kinase signaling in the tumor microenvironment: what do we need to consider when treating chronic lymphocytic leukemia with PI3K inhibitors? Front Immunol. 2021;11:595818. doi: 10.3389/fimmu.2020.595818
   PubMed Web of Science ®Google Scholar
• Galvão I, Queiroz-Junior CM, de Oliveira VLS, et al. The inhibition of Phosphoinositide-3 kinases induce resolution of inflammation in a gout model. Front Pharmacol. 2019;9:1505. doi: 10.3389/fphar.2018.01505
   PubMed Web of Science ®Google Scholar
• Galvão I, Melo EM, de Oliveira VLS, et al. Therapeutic potential of the FPR2/ALX agonist AT-01-KG in the resolution of articular inflammation. Pharmacol Res. 2021;165:105445. doi: 10.1016/j.phrs.2021.105445
   PubMed Web of Science ®Google Scholar
• Maimaitiyiming Y, Wang QQ, Yang C, et al. Hyperthermia selectively destabilizes oncogenic fusion proteins. Blood Cancer Discovery. 2021;2(4):388–401. doi: 10.1158/2643-3230.BCD-20-0188
   PubMedGoogle Scholar
• Wang QQ, Hussain L, Yu PH, et al. Hyperthermia promotes degradation of the acute promyelocytic leukemia driver oncoprotein ZBTB16/RARα. Acta Pharmacol Sin. 2023;44(4):822–831. doi: 10.1038/s41401-022-01001-6
   PubMed Web of Science ®Google Scholar
• Maimaitiyiming Y, Yang T, Wang QQ, et al. Heat treatment promotes ubiquitin-mediated proteolysis of SARS-CoV-2 RNA polymerase and decreases viral load. Research (Wash D C). 2022;2022:9802969. doi: 10.34133/2022/9802969
   PubMedGoogle Scholar
• Wang L, Zhan G, Maimaitiyiming Y, et al. m6A modification confers thermal vulnerability to HPV E7 oncotranscripts via reverse regulation of its reader protein IGF2BP1 upon heat stress. Cell Rep. 2022;41(4):111546. doi: 10.1016/j.celrep.2022.111546
   PubMedGoogle Scholar
• Markovic M, Stuhlmeier KM. Short-term hyperthermia prevents activation of proinflammatory genes in fibroblast-like synoviocytes by blocking the activation of the transcription factor NF-kappaB. J Mol Med (Berl). 2006;84(10):821–32. doi:10.1007/s00109-006-0089-6
   PubMed Web of Science ®Google Scholar
• Stuhlmeier KM. Short term hyperthermia prevents the activation of mitogen-activated protein kinase p38. Exp Gerontol. 2009;44(6–7):406–412. doi:10.1016/j.exger.2009.03.002
   PubMed Web of Science ®Google Scholar
• Ahn H, Lee G, Lee GS. Lower temperatures exacerbate NLRP3 inflammasome activation by promoting Monosodium urate crystallization, causing gout. Cells. 2021;10(8):1919. doi:10.3390/cells10081919
   PubMed Web of Science ®Google Scholar